A
Arthur A. Vandenbark
Researcher at Oregon Health & Science University
Publications - 134
Citations - 7372
Arthur A. Vandenbark is an academic researcher from Oregon Health & Science University. The author has contributed to research in topics: Experimental autoimmune encephalomyelitis & T cell. The author has an hindex of 41, co-authored 134 publications receiving 6920 citations. Previous affiliations of Arthur A. Vandenbark include Veterans Health Administration & United States Department of Veterans Affairs.
Papers
More filters
Journal ArticleDOI
Sex differences in the therapeutic effects of anti-PDL2 neutralizing antibody on stroke
Hilary A. Seifert,Hilary A. Seifert,Wenbin Zhu,Arthur A. Vandenbark,Arthur A. Vandenbark,Nabil J. Alkayed,Halina Offner,Halina Offner +7 more
TL;DR: It is found that anti-PDL2 neutralizing antibody treatment of MCAO significantly reduced infarct volumes in male mice but had no protective effects in female mice even at a 5-fold increased dose of anti- PDL2 mAb.
Journal ArticleDOI
Episodic changes in T‐cell frequencies to myelin basic protein in patients with multiple sclerosis
Arthur A. Vandenbark,Dennis Bourdette,Ruth H. Whitham,Yuan K. Chou,G. A. Hashim,Halina Offner +5 more
TL;DR: With late-emerging CN previously probably had small-amplitude CN that was not clinically apparent, but would have been detectable with ophthalmoscopic examination, and the term “congenital” refers to a congenital predisposition for ocular motor instability rather than the exact time of its manifestation.
Patent
Partial mhc constructs and methods of use
Arthur A. Vandenbark,Gregory G. Burrows,Roberto Meza-Romero,Gil Benedek,Shayne Andrew,Jeffery L. Mooney +5 more
TL;DR: In this article, isolated major histocompatibility complex (MHC) class II α 1 domain polypeptides and methods of use are discussed. And methods of evaluating efficacy of treatment or optimizing treatment of a subject with a poly-peptide including an MHC class IIα 1 domain or poly-protein, such as a β1α1 RTL.
Journal ArticleDOI
Prevention and treatment of experimental autoimmune encephalomyelitis with clonotypic CDR3 peptides: CD4(+) Foxp3(+) T-regulatory cells suppress interleukin-2-dependent expansion of myelin basic protein-specific T cells.
Abigail C. Buenafe,Shayne Andrew,Michael Afentoulis,Halina Offner,Halina Offner,Arthur A. Vandenbark,Arthur A. Vandenbark +6 more
TL;DR: It is demonstrated that TCR CDR3 peptides from the transgenic TCR can provide a protective effect when therapy is initiated before the induction of experimental autoimmune encephalomyelitis (EAE) and can ameliorate the disease when administered after EAE onset.
Journal ArticleDOI
Multiple class I motifs revealed by sequencing naturally processed peptides eluted from rat T cell MHC molecules
Gregory G. Burrows,K. Ariail,Bozena Celnik,J.E. Gambee,Halina Offner,Halina Offner,Arthur A. Vandenbark,Arthur A. Vandenbark +7 more
TL;DR: In this paper, the authors characterized the Lewis rat Vbeta8.2+ T cell hybridoma C14/BW12-12A1 by FACS analysis and have used immunoaffinity chromatography to purify class I molecules from these cells.